Fenbendazole for humans cancer is becoming a popular treatment after a number of fenbendazole cancer success stories. One of the most famous success stories involves a man with stage 4 small cell lung cancer who was given a 3-month life expectancy and started taking fenbendazole (Panacur C) and other supplements, which led to a dramatic improvement in his health. The case of this patient has drawn attention to the need for a government-led communication system that can promptly deliver evidence-based information from experts when controversial information becomes a social issue.
While anthelmintics used to treat parasites in animals have been examined as potential cancer treatments, none of the anthelmintic drugs has been approved for human use by Health Canada. However, two of the drugs in this class have been tested and demonstrated to be effective cancer treatments in a laboratory setting. In addition, many patients are using antiparasitic medications and supplements to treat their cancer and have reported positive results.
In the present study, a focus group interview was conducted with 21 people who were diagnosed with non-small cell lung cancer and self-administered fenbendazole. The participants were surveyed using a semi-structured questionnaire, which consisted of three categories: (1) acquisition channel of general cancer information and false information on fenbendazole; (2) quality of obtained information; and (3) perception toward the information.
Among the 21 lung cancer patients, most first heard about the anticancer effects of fenbendazole from acquaintances or family members, followed by TV and YouTube. The majority of them did not understand the origin or reliability of the information they received and perceived it as unreliable.
Research results have shown that fenbendazole has cytotoxic properties and is effective in killing cancer cells by inhibiting the synthesis of microtubules. In addition, it also induces apoptosis in cancer cells by activating the p53 tumour suppressor gene.
However, the effects of fenbendazole on cancer are complex and not fully understood. Some researchers speculate that fenbendazole may interfere with microtubules by binding to tubulin and blocking its polymerization. Moreover, it could induce the apoptosis of cancer cells by interfering with the cell cycle.
Other researchers have also found that fenbendazole has anti-tumour effects in human non-small-cell lung cancer cells. It can prevent the formation of a cellular mitotic spindle and inhibit the progression from G2 to anaphase by directly binding to cyclin B1 and preventing its phosphorylation.
In a trial in which mice were fed fenbendazole, the researchers found that the drug reduced tumour size and weight. The researchers concluded that fenbendazole could have similar anti-tumour effects in humans and should be studied further to determine its efficacy as an alternative cancer treatment. The results of the trial were published in a journal article in 2020. However, it is important to note that the results of this study were not peer-reviewed and were based on anecdotal reports from individuals who claimed to have experienced cancer cures after taking fenbendazole. In addition, this report did not examine whether the fenbendazole was combined with any other therapies or supplements. fenbendazole for humans cancer